Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tenofovir Alafenamide vs Entecavir vs Tenofovir Disoproxil Fumarate in HBV-related ACLF
NCT03920618Recruiting
- Sponsor
- The Third Affiliated Hospital of Sun Yat-sen University
- Start
- Feb 2019
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of tenofovir alafenamide in hepatitis B (HBV) and acute-on-chronic liver failure (ACLF) (3 arms), sponsored by The Third Affiliated Hospital of Sun Yat-sen University. Primary endpoint: Survival rate in the follow-up at 144 weeks. Started Feb 2019; status: recruiting.
02
Drugs
tenofovir alafenamide
03
Conditions
hepatitis B (HBV)acute-on-chronic liver failure (ACLF)
Beyond the preview
Go deeper on NCT03920618.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03920618.